Clinical trial registry record

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 2, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06731413
Last registry update
June 2, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
Virginia Commonwealth University
Enrollment
40
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
40
Population
ALL · 18 Years
Duration
2025-02-11 to 2033-07-30
Intervention
Reduced Dose of Chemotherapy and Immunotherapy
Comparator
Not reported
Outcomes measured
Occurrence of chemotherapy discontinuation due to treatment-related adverse events — Through completion of protocol the…; Response (complete response and partial response) per Response Evaluation Criteria in Solid Tumors — Up to 5 years; Overall incidence and severity of all adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE)…; Overall survival defined as the time from the date of first study treatment until the date of death. Overall survival (…; Progression-free survival (PFS) measured from the date of first study treatment until the date of documented disease pr…; Cancer related symptoms and quality of life — Baseline, Cycle 3 Day 1, Cycle 5 Day 1 Cycle 9 Day 1, EOT Visit (up to 2…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON